Waldencast plc - Class A Ordinary Share (NQ:WALD)

1.650 -0.030 (-1.79%)

Streaming Delayed Price Updated: 10:54 AM EDT, Jul 7, 2026 Add to My Watchlist

Price and Volume

Volume	55,095
Open	1.670
Bid (Size)	1.630 (900)
Ask (Size)	1.650 (300)
Prev. Close	1.680
Today's Range	1.621 - 1.680
52wk Range	0.7200 - 3.220
Shares Outstanding	9,342,874
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Obagi Medical Announces FDA Approval of Obagi® saypha® ChIQ™ Injectable Hyaluronic Acid Gel

June 15, 2026

Approval Further Expands Obagi Medical’s Injectable Portfolio and Strengthens Its Position as a Leading Dermatological Megabrand

From Waldencast plc

Via GlobeNewswire

Which stocks are experiencing notable movement on Monday? ↗

June 01, 2026

Via Chartmill

Performance

YTD	-3.5%	-3.5%
1 Month	+0.6%	+0.6%
3 Month	+67.3%	+67.3%
6 Month	+1.9%	+1.9%
1 Year	-37.9%	-37.9%

More News

Waldencast Announces Sale of Obagi Medical to Bridgepoint

June 01, 2026

From Waldencast plc

Via GlobeNewswire

Obagi Medical Shares New Data on Recent Innovations at Music City Symposium for Cosmetic Advances & Laser Education (SCALE) Meeting

May 15, 2026

From Waldencast plc

Via GlobeNewswire

Obagi and Next Health Partner to Launch “The Skin Recharge Station” Pop-Up Experience

May 14, 2026

From Waldencast plc

Via GlobeNewswire

Unusual volume stocks are being observed in Thursday's session. ↗

April 30, 2026

Via Chartmill

Obagi Medical Unveils New Mineral Sunscreen Designed to Protect Sensitive and Post-Procedure Skin*

April 30, 2026

From Waldencast plc

Via GlobeNewswire

Get insights into the top gainers and losers of Wednesday's pre-market session. ↗

April 29, 2026

Via Chartmill

Waldencast announces conclusion of SEC investigation

April 28, 2026

From Waldencast plc

Via GlobeNewswire

Obagi Medical Introduces NU-GEN™ Cellular Renewal Serum Designed to Visibly Rewind Skin’s Age and Restore Visible Youthfulness

March 24, 2026

From Waldencast plc

Via GlobeNewswire

Obagi Medical and ProMD Announce Collaboration in the ALOHA Program to Advance Clinical Evidence with Obagi® saypha® MagIQ™

March 19, 2026

From Waldencast plc

Via GlobeNewswire

Waldencast Reports Q4 2025 and FY 2025 Financial Results

March 13, 2026

From Waldencast plc

Via GlobeNewswire

Waldencast plc Announces Fourth Quarter and Fiscal Year 2025 Earnings Date

March 11, 2026

From Waldencast plc

Via GlobeNewswire

Obagi Medical and Schweiger Dermatology Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™

February 27, 2026

From Waldencast plc

Via GlobeNewswire

Obagi Medical and It’s a Secret Med Spa Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™

February 25, 2026

From Waldencast plc

Via GlobeNewswire

Obagi Medical and Aesthetic Record Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™

February 17, 2026

From Waldencast plc

Via GlobeNewswire

Obagi Medical and DermFx Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™

February 06, 2026

From Waldencast plc

Via GlobeNewswire

Obagi Medical and Moxie Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™

February 05, 2026

From Waldencast plc

Via GlobeNewswire

Obagi Medical Introduces New Lip Therapy Protocol Designed to Resurface, Replenish, and Protect

February 03, 2026

From Waldencast plc

Via GlobeNewswire

Obagi Medical and VIO Med Spa Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™

January 30, 2026

From Waldencast plc

Via GlobeNewswire

Obagi Medical and Next Health Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™

January 28, 2026

From Waldencast plc

Via GlobeNewswire

UPDATE - Obagi Medical and Alpha Aesthetic Partners Announce Their Collaboration in the ALOHA Program to Drive Real-World Evidence with Obagi® saypha® MagIQ™

January 27, 2026

From Waldencast plc

Via GlobeNewswire

Obagi Medical and Alpha Aesthetic Partners Announce Their Collaboration in the ALOHA Program to Drive Real-World Evidence with Obagi® saypha® MagIQ™

January 27, 2026

From Waldencast plc

Via GlobeNewswire

CORRECTION – Obagi Medical and Platinum Dermatology Partners Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™

January 26, 2026

From Waldencast plc

Via GlobeNewswire

Obagi Medical and Platinum Dermatology Partners Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™

January 26, 2026

From Waldencast plc

Via GlobeNewswire

Frequently Asked Questions

Is Waldencast plc - Class A Ordinary Share publicly traded?

Yes, Waldencast plc - Class A Ordinary Share is publicly traded.

What exchange does Waldencast plc - Class A Ordinary Share trade on?

Waldencast plc - Class A Ordinary Share trades on the Nasdaq Stock Market

What is the ticker symbol for Waldencast plc - Class A Ordinary Share?

The ticker symbol for Waldencast plc - Class A Ordinary Share is WALD on the Nasdaq Stock Market

What is the current price of Waldencast plc - Class A Ordinary Share?

The current price of Waldencast plc - Class A Ordinary Share is 1.650

When was Waldencast plc - Class A Ordinary Share last traded?

The last trade of Waldencast plc - Class A Ordinary Share was at 07/07/26 10:54 AM ET

What is the market capitalization of Waldencast plc - Class A Ordinary Share?

The market capitalization of Waldencast plc - Class A Ordinary Share is 15.42M

How many shares of Waldencast plc - Class A Ordinary Share are outstanding?

Waldencast plc - Class A Ordinary Share has 15M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.